Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 MAIA Study

被引：0

作者：

Kumar, S. K. ^{[1
]}

Moreau, P. ^{[2
]}

Bahlis, N. ^{[3
]}

Facon, T. ^{[4
]}

Plesner, T. ^{[5
,6
]}

Orlowski, R. Z. ^{[7
]}

Basu, S. ^{[8
,9
]}

Nahi, H. ^{[10
]}

Hulin, C. ^{[11
]}

Quach, H. ^{[12
]}

Goldschmidt, H. ^{[13
,14
]}

O'Dwyer, M. ^{[15
]}

Perrot, A. ^{[16
]}

Venner, C. P. ^{[17
,18
]}

Weisel, K. ^{[19
]}

Raje, N. ^{[20
]}

Tiab, M. ^{[21
]}

Macro, M. ^{[22
]}

Frenzel, L. ^{[23
]}

Leleu, X. ^{[24
]}

Wang, G. ^{[25
]}

Krevvata, M. ^{[25
]}

Carson, R. ^{[25
]}

Borgsten, F. ^{[26
]}

Usmani, S. Z. ^{[27
]}

机构：

[1] Mayo Clin Rochester, Dept Hematol, Rochester, MN USA

[2] Univ Hosp Hotel Dieu, Hematol Dept, Nantes, France

[3] Univ Calgary, Arnie Charbonneau Canc Res Inst, Calgary, AB, Canada

[4] Univ Lille, CHU Lille, Serv Malad Sang, Lille, France

[5] Vejle Hosp, Vejle, Denmark

[6] Univ Southern Denmark, Vejle, Denmark

[7] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[8] Royal Wolverhampton NHS Trust, Wolverhampton, England

[9] Wolverhampton Univ, CRN West Midlands, NIHR, Wolverhampton, England

[10] Karolinska Inst, Karolinska Univ Hosp Huddinge, Div Hematol, Dept Med, Stockholm, Sweden

[11] Univ Hosp, Dept Hematol, Hop Haut Leveque, Pessac, France

[12] Univ Melbourne, St Vincents Hosp, Melbourne, Vic, Australia

[13] Univ Hosp Heidelberg, Internal Med 5, Heidelberg, Germany

[14] Natl Ctr Tumor Dis NCT, Heidelberg, Germany

[15] NUI, Dept Med Haematol, Galway, Ireland

[16] Univ Toulouse, CHU Toulouse, Serv Hematol, IUCT O,UPS, Toulouse, France

[17] Univ Alberta, Cross Canc Inst, Dept Med Oncol, Edmonton, AB, Canada

[18] BC Canc, Vancouver Ctr Grp, Vancouver, BC, Canada

[19] Univ Med Ctr Hamburg Eppendorf, Sect Pneumol, Dept Oncol Hematol & Bone Marrow Transplantat, Hamburg, Germany

[20] Massachusetts Gen Hosp, Canc Ctr, Ctr Multiple Myeloma, Boston, MA 02114 USA

[21] CHD Vendee, La Roche Sur Yon, France

[22] Ctr Hosp Univ CHU Caen, Caen, France

[23] Hop Necker Enfants Malad, Paris, France

[24] CHU Poitiers, Hop Miletrie, Poitiers, France

[25] Janssen Res & Dev LLC, Spring House, PA USA

[26] Janssen Res & Dev LLC, Raritan, NJ USA

[27] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P342

引用

页码：183 / 184

页数：2

共 50 条

[31] Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Jakubowiak, Andrzej
Usmani, Saad Z.
Krishnan, Amrita
Lonial, Sagar
Comenzo, Raymond L.
Wang, Jianping
de Boer, Carla
Deraedt, William
Weiss, Brendan M.
Schecter, Jordan M.
Chari, Ajai
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10): : 701 - 710
[32] MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab plus daratumumab plus lenalidomide (EDR) versus daratumumab plus lenalidomide plus dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM)
Kull, M.
Grosicki, S.
Yeh, S. -P.
Huang, J. S. Y.
Byun, J. M.
DiRienzo, C.
Viqueira, A.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 314 - 314
[33] MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab plus daratumumab plus lenalidomide (EDR) versus daratumumab plus lenalidomide plus dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM).
Grosicki, Sebastian
Yeh, Su-Peng
Huang, Jeffrey S. Y.
Byun, Ja Min
DiRienzo, Christine
Viqueira, Andrea
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[34] Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
Facon, Thierry
Kumar, Shaji K.
Plesner, Torben
Orlowski, Robert Z.
Moreau, Philippe
Bahlis, Nizar
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Weisel, Katja
Mace, Joseph R.
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Ahmadi, Tahamtan
Wang, Jianping
Van Rampelbergh, Rian
Uhlar, Clarissa M.
Tromp, Brenda
Delioukina, Maria
Vermeulen, Jessica
Usmani, Saad Z.
LANCET ONCOLOGY, 2021, 22 (11): : 1582 - 1596
[35] EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS RD ALONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: UPDATED ANALYSIS OF POLLUX
Dimopoulos, M. A.
Moreau, P.
Nahi, H.
Plesner, T.
Goldschmidt, H.
Suzuki, K.
Orlowski, R. Z.
Rabin, N.
Leiba, M.
Oriol, A.
Chari, A.
San-Miguel, J.
Richardson, P. G.
Usmani, S. Z.
O'Rourke, L.
Wu, K.
Casneuf, T.
Chiu, C.
Qin, X.
Bahlis, N. J.
HAEMATOLOGICA, 2017, 102 : 108 - 109
[36] A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
O'Donnell, Elizabeth
Laubach, Jacob P.
Yee, Andrew J.
Huff, Carol Ann
Basile, Frank
Wade, Philip M.
Paba-Prada, Claudia E.
Ghobrial, Irene M.
Schlossman, Robert L.
Couture, Nicole
Doherty, Lauren
Lyons, Hannah
English, Caroline
Munshi, Nikhil
Anderson, Kenneth C.
Richardson, Paul G.
Raje, Noopur
BLOOD, 2014, 124 (21)
[37] UPDATED EFFICACY AND SAFETY ANALYSIS OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRd) VERSUS LENALIDOMIDE AND DEXAMETHASONE (Rd) FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM; POLLUX)
Moreau, P.
White, D.
Benboubker, L.
Cook, G.
Leiba, M.
Morton, J.
Ho, P. J.
Kim, K.
Takezako, N.
Trivedi, S.
Wu, K.
Casneuf, T.
Chiu, C.
Schecter, J. M.
Dimopoulos, M. A.
HAEMATOLOGICA, 2018, 103 : 31 - 31
[38] Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Pollux
Dimopoulos, Meletios A.
White, Darrell J.
Benboubker, Lofti
Cook, Gordon
Leiba, Merav
Morton, James
Ho, P. Joy
Kim, Kihyun
Takezako, Naoki
Trivedi, Sonali
Wu, Kaida
Casneuf, Tineke
Chiu, Christopher
Schecter, Jordan
Moreau, Philippe
BLOOD, 2017, 130
[39] Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM).
Orlowski, Robert Z.
Goldschmidt, Hartmut
Cavo, Michele
Martin, Thomas G.
Paux, Gautier
Oprea, Corina
Facon, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[40] Sustained Improvement in HealthRelated Quality of Life in TransplantIneligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial
Perrot, Aurore
Facon, Thierry
Kumar, Shaji
Plesner, Torben
Orlowski, Robert Z.
Moreau, Philippe
Bahlis, Nizar J.
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael E.
Venner, Chris P.
Weisel, Katja
Mace, Joseph R.
Raje, Noopur S.
Tiab, Mourad
Macro, Magaret
Frenzel, Laurent
Leleu, Xavier
Liu, Kevin
Fastenau, John
Gries, Katharine S.
Ho, Kai Fai
Mistry, Pankaj
Tromp, Brenda
Delioukina, Maria
Vermeulen, Jessica
Usmani, Saad Z.
BLOOD, 2021, 138

← 1 2 3 4 5 →